Participate in an interactive, discussion-led session with industry experts to exchange diverse perspectives and solve complex industry challenges within the obesity drug development space without formal presentations.

• Standardizing “High-Quality Weight Loss” (HQWL) indices as a core regulatory endpoint to move beyond “undifferentiated-mass-reduction” as the gold standard for adult and geriatric success, leading to a more nuanced and accurate reflection of metabolic health across the aging spectrum
• Evaluating the ethics and logistics of “metabolic-reset” benchmarks to track the off-treatment persistence of weight stability, building the robust safety database required for universal payer approval and long-term chronic management
• Integrating objective functional outcome assessments (FOAs) regarding “physical-resilience” and “metabolic-reserve” to capture the human impact of treatment, ensuring that drug development remains focused on functional longevity rather than just cosmetic weight loss